Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, STELARA provides a new therapeutic option for children six years of age and older living with active psoriatic ...
Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...
Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback